GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Harvard Bioscience Inc (STU:HBI) » Definitions » Deferred Tax

Harvard Bioscience (STU:HBI) Deferred Tax : €0.61 Mil (TTM As of Jun. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Harvard Bioscience Deferred Tax?

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

Harvard Bioscience's change in deferred tax for the three months ended in Jun. 2024 was €0.21 Mil. Its change in deferred tax for the trailing twelve months (TTM) ended in Jun. 2024 was €0.61 Mil.

Harvard Bioscience Deferred Tax Historical Data

The historical data trend for Harvard Bioscience's Deferred Tax can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Harvard Bioscience Deferred Tax Chart

Harvard Bioscience Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Deferred Tax
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.36 -0.02 -0.29 -0.39 0.31

Harvard Bioscience Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Deferred Tax Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.13 0.01 0.22 0.16 0.21

Harvard Bioscience Deferred Tax Calculation

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

Deferred Tax for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.61 Mil.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Harvard Bioscience Deferred Tax Related Terms

Thank you for viewing the detailed overview of Harvard Bioscience's Deferred Tax provided by GuruFocus.com. Please click on the following links to see related term pages.

Harvard Bioscience Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Harvard Bioscience Inc (STU:HBI) » Definitions » Deferred Tax
Comparable Companies
AKYA INFU KRMD MLSS PDEX STXS BNGO UEEC DXR POCI ISRG XPAR:EL BDX TSE:7741 XSWX:ALC RMD OCSE:COLO B TSE:4543 XSWX:STMN WST
Traded in Other Exchanges
HBIO:USA HBI:Germany
Address
84 October Hill Road, Holliston, MA, USA, 01746
Website
https://www.harvardbioscience.com
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life science and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab.. The majority of its revenue comes from the United States.